Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

類似資料

• Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
  著者:: You, Ruxu, 等
  出版事項: (2020)
• Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
  著者:: Ruxu You, 等
  出版事項: (2020-04-01)
• Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
  著者:: Tan, Ping-Tee, 等
  出版事項: (2018)
• Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
  著者:: You, Ruxu, 等
  出版事項: (2018)
• Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
  著者:: Wu, Yi-Long, 等
  出版事項: (2018)